Nabriva Therapeutics (NASDAQ:NBRV) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04, Fidelity Earnings reports. Nabriva Therapeutics had a negative return on equity of 139.52% and a negative net margin of 3,602.24%. The company had revenue of $6.92 million for the quarter, compared to the consensus estimate of $1.23 million.
Shares of NBRV stock traded up $0.15 during midday trading on Wednesday, reaching $2.13. 2,494,200 shares of the stock were exchanged, compared to its average volume of 1,102,810. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $3.27. The company’s 50 day moving average is $1.94 and its two-hundred day moving average is $2.21. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.56. The firm has a market cap of $1.52 billion, a PE ratio of -1.31 and a beta of 2.42.
NBRV has been the topic of a number of research analyst reports. Northland Securities set a $13.00 price target on Nabriva Therapeutics and gave the company a “buy” rating in a report on Friday, August 16th. BidaskClub upgraded Nabriva Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Wedbush restated an “outperform” rating and set a $5.00 price target on shares of Nabriva Therapeutics in a report on Friday, August 9th. Bank of America set a $6.00 price target on Nabriva Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 20th. Finally, HC Wainwright set a $7.00 price target on Nabriva Therapeutics and gave the company a “buy” rating in a report on Sunday, August 18th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Nabriva Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.06.
In other news, CEO Theodore R. Schroeder bought 50,000 shares of Nabriva Therapeutics stock in a transaction on Tuesday, August 27th. The shares were purchased at an average price of $1.79 per share, for a total transaction of $89,500.00. Following the acquisition, the chief executive officer now owns 5,786 shares of the company’s stock, valued at $10,356.94. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have acquired 64,977 shares of company stock worth $119,951 and have sold 21,773 shares worth $45,186. 3.32% of the stock is currently owned by corporate insiders.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Story: Balance Sheet
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.